Actively Recruiting

Age: 18Years - 80Years
MALE
NCT06163924

The Effect of Multidisciplinary Care Approach on CV Risk Modification in CaP Patients Receiving ADT

Led by Chinese University of Hong Kong · Updated on 2025-05-06

130

Participants Needed

1

Research Sites

276 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Prostate cancer is characterised by its slow progression nature, and even for metastatic disease, the 5-year survival is up to 30%. While ADT can effectively control disease, there is increasing evidence suggesting that it can also result in many adverse cardiovascular side effects on the patients, and these effects are particularly important due to the prolonged survival of these patients. There are suggestions that close cardiovascular (CV) monitoring will help to reduce cardiovascular risk and related morbidities. However, there is limited data to show the positive impact of these monitoring could reducing CV risk and morbidities. Moreover, information regarding the optimal follow-up approach and schedule is also lacking. Therefore, there is a need to have more information on the approach to monitoring the CV risk and the real-life impact of this monitoring on our patients. Patients diagnosed with prostate cancer and plan to receive ADT are invited to participate in this study to assess the potential benefit of multidisciplinary care approach to CV risk modification.

CONDITIONS

Official Title

The Effect of Multidisciplinary Care Approach on CV Risk Modification in CaP Patients Receiving ADT

Who Can Participate

Age: 18Years - 80Years
MALE

Eligibility Criteria

Eligible

You may qualify if you...

  • Adult men 18 to 80 years old
  • Histologically or clinically diagnosed prostate cancer
  • Planned to receive androgen deprivation therapy for at least 1 year
Not Eligible

You will not qualify if you...

  • History of major atherosclerotic cardiovascular disease within the past 12 months, including recent acute coronary syndrome, myocardial infarction, ischemic stroke, or symptomatic peripheral arterial disease
  • Prior neoadjuvant or adjuvant hormone therapy within 1 year before enrollment
  • Refusal or inability to provide written informed consent
  • Participation in another investigational program with interventions outside routine clinical practice

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

The Chinese University of Hong Kong

Hong Kong, Hong Kong

Actively Recruiting

Loading map...

Research Team

C

Chi Fai NG, Professor

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here